Abstract
Chronic rhinosinusitis (CRS) is a prevalent and debilitating inflammatory condition of the nasal and paranasal sinuses, with multifactorial and often ill-defined pathophysiology, leading to major quality-of-life impairments. Current therapies largely aim at symptom control rather than remission or cure, leaving many patients with uncontrolled disease. This doctoral thesis sought to improve CRS care by identifying 1) characterizing the reasons for uncontrolled disease, 2) evaluating the real-world efficacy of two therapeutic molecules omalizumab and mepolizumab for CRSwNP, 3) examining epithelial and immunological responses to dupilumab to explore the disease-modifying effect and 4) investigating the effects of an INCS molecule on Covid-related immune effects on the epithelial barrier. We highlighted the impact of epithelial barrier dysfunction in uncontrolled disease, hence supporting the need to consider disease-modifying treatments in the future. We confirmed the effects of biologicals and showed barrier restoring and potential disease-modifying effects of dupilumab. Furthermore, we showed a potential role for the restoration of the nasal epithelial barrier as a preventive strategy against viral infections.